Iron Supplements Are Safe for G6PD Deficiency Patients
Iron supplements, both oral and intravenous, are safe to use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and do not cause hemolysis. Iron is not among the medications that trigger oxidative stress-induced hemolytic crises in G6PD-deficient individuals.
Evidence-Based Safety Profile
The most comprehensive and recent pharmacogenetics review explicitly addresses this concern. A 2023 systematic evidence review of medications in G6PD deficiency found no evidence contraindicating iron supplementation 1. An earlier 2010 systematic review similarly concluded that iron preparations can be given safely in normal therapeutic doses to G6PD-deficient patients, finding no solid evidence to prohibit their use 2.
Research examining iron metabolism in G6PD-deficient patients under steady-state conditions demonstrates that these individuals maintain normal iron status without developing iron overload or deficiency, despite chronic low-grade hemolysis 3. Studies of iron parameters in G6PD-deficient subjects show similar hemoglobin and serum iron concentrations compared to normal individuals 4.
Recommended Dosing Regimen for Iron-Deficiency Anemia
First-Line: Oral Iron Therapy
Start with ferrous sulfate 200 mg once daily or every other day 5. The 2011 British Society of Gastroenterology guidelines recommend ferrous sulfate 200 mg twice daily as the standard approach 5, though recent evidence suggests alternate-day dosing may optimize absorption while reducing side effects 6.
Key dosing principles:
- Single morning doses maximize absorption (avoid afternoon/evening dosing after a morning dose)
- Doses ≥60 mg stimulate hepcidin elevation lasting 24 hours, reducing absorption of subsequent doses
- Alternate-day dosing (60-120 mg) may achieve better total iron absorption than daily divided doses 6
- Continue for 3 months after iron deficiency correction to replenish stores 5
- Alternative oral formulations (ferrous fumarate, ferrous gluconate) are equally effective if ferrous sulfate is not tolerated 5
Monitor response: Hemoglobin should rise by 2 g/dL within 3-4 weeks 7. Check hemoglobin at 4 weeks to confirm response 8.
Second-Line: Intravenous Iron
Use IV iron if oral iron is not tolerated, ineffective, or absorption is compromised 5, 9. This is particularly relevant for:
- Inflammatory bowel disease with active inflammation 9
- Post-bariatric surgery patients 9
- Malabsorption syndromes
- Intolerance to multiple oral formulations
IV iron options (from 2011 guidelines) 5:
- Iron sucrose (Venofer): 200 mg over 10 minutes
- Ferric carboxymaltose (Ferinject): 1000 mg over 15 minutes (preferred for single-dose replacement)
- Iron dextran (Cosmofer): 20 mg/kg over 6 hours (higher anaphylaxis risk: 0.6-0.7%)
The 2024 AGA guidelines recommend formulations requiring 1-2 infusions over those requiring multiple visits 9.
Critical Pitfalls to Avoid
Do not confuse iron with primaquine: The only medication-related concern in G6PD deficiency involves antimalarials like primaquine, which should be limited to ≤5 days in populations with severe G6PD deficiency due to hemolysis risk 10. Iron has no such restriction.
Do not delay iron therapy: Iron replacement should not be deferred while awaiting investigations for iron-deficiency anemia unless colonoscopy is imminent 8.
Do not assume all oxidative stressors are medications: Infections and diabetic ketoacidosis can trigger hemolysis in G6PD deficiency 11, but this does not implicate iron supplementation.
G6PD-Specific Considerations
G6PD-deficient patients experience chronic low-grade hemolysis with reticulocytosis and reduced haptoglobin 3, but this does not alter iron supplementation requirements or safety. These patients maintain normal iron balance and do not develop iron overload from their baseline hemolysis 3. Standard iron replacement protocols apply without modification for G6PD deficiency status.